Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 35Lymphoma, Large B-Cell, Diffuse 22Sarcoma 19Lymphoma 19Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Non-Hodgkin 9Hodgkin Disease 9Multiple Myeloma 8Leukemia 8Neuroblastoma 6Liver Neoplasms 6Lymphoma, Follicular 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Liposarcoma 3Leiomyosarcoma 3Chondrosarcoma 3Burkitt Lymphoma 3Wilms Tumor 2Rhabdomyosarcoma 2

Interventions

CTLA-4 Antigen 2envafolimab 1Radiosurgery 1Radiation 1Paclitaxel 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Diabetes Mellitus, Insulin-Dependent, 12 × Doxorubicin × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡